Skip to main content
SpringerLink
Log in

Anti-synthetase syndrome and the risk of progressive pulmonary fibrosis: weighting of concomitant anti-Ro/SSA antibodies

  • Letter to the Editor
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fu H, Zheng Z, Zhang Z et al (2023) Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease. Clin Rheumatol. https://doi.org/10.1007/s10067-023-06570-3

  2. Wodkowski M, Hudson M, Proudman S et al (2015) Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. Clin Exp Rheumatol 33:S131–S135

    PubMed  Google Scholar 

  3. Meridor K, Sagy I, Molad Y (2022) Anti-Ro/SS-A antibody is associated with worse pulmonary outcome and reduced overall survival in systemic sclerosis. Mod Rheumatol 32:1086–1093. https://doi.org/10.1093/mr/roab118

    Article  PubMed  Google Scholar 

  4. Gunnarsson R, El-Hage F, Aaløkken TM et al (2016) Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease. Rheumatology (Oxford) 55:103–108. https://doi.org/10.1093/rheumatology/kev300

    Article  PubMed  Google Scholar 

  5. Sabbagh S, Pinal-Fernandez I, Kishi T et al (2019) Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis 78:988–995. https://doi.org/10.1136/annrheumdis-2018-215004

    Article  CAS  PubMed  Google Scholar 

  6. Lv C, You H, Xu L et al (2023) Coexistence of anti-Ro52 antibodies in anti-MDA5 antibody-positive dermatomyositis is highly associated with rapidly progressive interstitial lung disease and mortality risk. J Rheumatol 50:219–226. https://doi.org/10.3899/jrheum.220139

    Article  CAS  PubMed  Google Scholar 

  7. Gui X, Shenyun S, Ding H et al (2022) Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease. Rheumatology (Oxford) 61:4570–4578. https://doi.org/10.1093/rheumatology/keac090

    Article  CAS  PubMed  Google Scholar 

  8. Vojinovic T, Cavazzana I, Ceruti P et al (2020) Predictive features and clinical presentation of interstitial lung disease in inflammatory myositis. Clin Rev Allergy Immunol 60:87–94. https://doi.org/10.1007/s12016-020-08814-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Xing X, Li A, Li C et al (2020) Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis. Respir Med 172:106134. https://doi.org/10.1016/j.rmed.2020.106134

    Article  PubMed  Google Scholar 

  10. Marie I, Hatron PY, Dominique S et al (2012) Shortterm and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 41:890–899

    Article  CAS  PubMed  Google Scholar 

  11. Shi J, Li S, Yang H et al (2017) Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol 44:1051–1057. https://doi.org/10.3899/jrheum.161480

    Article  CAS  PubMed  Google Scholar 

  12. Zhao Y, Zhang C, Su H et al (2023) Predictive factors for progressive fibrosing interstitial lung disease in anti-synthetase syndrome. Int J Rheum Dis. https://doi.org/10.1111/1756-185X.14664

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Camino del Molino, 2, 28942, Fuenlabrada, Madrid, Spain

    David Bernal-Bello, Jorge Rodríguez-Rodríguez, Miguel Ángel Duarte-Millán & Begoña Frutos-Pérez

Authors
  1. David Bernal-Bello
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jorge Rodríguez-Rodríguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miguel Ángel Duarte-Millán
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Begoña Frutos-Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the conception and design of the manuscript, the first draft of which was written by David Bernal-Bello and Jorge Rodríguez-Rodríguez. All authors read, revised and approved the final version of the manuscript.

Corresponding author

Correspondence to David Bernal-Bello.

Ethics declarations

Disclosures

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bernal-Bello, D., Rodríguez-Rodríguez, J., Duarte-Millán, M.Á. et al. Anti-synthetase syndrome and the risk of progressive pulmonary fibrosis: weighting of concomitant anti-Ro/SSA antibodies. Clin Rheumatol 42, 2249–2250 (2023). https://doi.org/10.1007/s10067-023-06615-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-023-06615-7

Search

Navigation